Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma
Piotr T. Wysocki, Paulina Chmiel, Jacek Jassem, Leszek Kraj · 2026
Read Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma by Piotr T. Wysocki, Paulina Chmiel, Jacek Jassem, Leszek Kraj (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13197303.txt.
Description
Piotr T Wysocki and colleagues review later-line treatment for advanced liver cancer in 2026. Hepatocellular carcinoma is the main form of liver cancer. Many patients are found at a late stage, so drug therapy is the chief option, and care has shifted toward immune drug blends.
More patients now reach second-line and later care, yet firm rules for choosing among options are lacking. Options include targeted drugs, immune checkpoint drugs, which release brakes on immune cells, and blends of both. Proof of benefit and of who gains most stays thin. The review sums up recent gains and new tactics, aiming to guide choices in a fast-changing field.
Catalog record
| CREATOR | Piotr T. Wysocki, Paulina Chmiel, Jacek Jassem, Leszek Kraj |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 124 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |